Effect of Prolonged-Release Pirfenidone on Renal Function in Septic Acute Kidney Injury Patients: A Double-Blind Placebo-Controlled Clinical Trial
Background. There is no treatment for septic acute kidney injury (sAKI). The anti-inflammatory activity of prolonged-release pirfenidone (PR-PFD) could be beneficial in this clinical setting. Methods. This study was a double-blind randomized clinical trial in sAKI patients with nephrology consultati...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2021-01-01
|
| Series: | International Journal of Nephrology |
| Online Access: | http://dx.doi.org/10.1155/2021/8833278 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841524566874128384 |
|---|---|
| author | Jonathan S. Chávez-Iñiguez Jorge L. Poo Miguel Ibarra-Estrada Leonel García-Benavides Guillermo Navarro-Blackaller Cynthia Cervantes-Sánchez Eduardo Nungaray-Pacheco Ramón Medina-González Juan Armendariz-Borunda Guillermo García-García |
| author_facet | Jonathan S. Chávez-Iñiguez Jorge L. Poo Miguel Ibarra-Estrada Leonel García-Benavides Guillermo Navarro-Blackaller Cynthia Cervantes-Sánchez Eduardo Nungaray-Pacheco Ramón Medina-González Juan Armendariz-Borunda Guillermo García-García |
| author_sort | Jonathan S. Chávez-Iñiguez |
| collection | DOAJ |
| description | Background. There is no treatment for septic acute kidney injury (sAKI). The anti-inflammatory activity of prolonged-release pirfenidone (PR-PFD) could be beneficial in this clinical setting. Methods. This study was a double-blind randomized clinical trial in sAKI patients with nephrology consultation at the Civil Hospital of Guadalajara, in addition to the usual treatment of AKI associated with sepsis; patients were randomized to receive either PR-PFD at 1,200 mg/day (group A) or 600 mg/day (group B) or a matched placebo for 7 consecutive days. The primary objective was the decrease in serum creatinine (sCr) and increase in urinary volume (UV); the secondary objectives were changes in serum electrolytes, acid-base status, and mortality. Results. Between August 2016 and August 2017, 88 patients were randomized. The mean age was 54 (17 ± SD) years, and 47% were male. The main site of infection was the lung (39.8%), septic shock was present in 39.1% of the cases, and the mean SOFA score was 8.8 points. 28 patients received PFD 1,200 mg, 30 patients received PFD 600 mg, and 30 patients received placebo. During the study, sCr did not differ among the groups. The reversion rate of sCr, UV, and mortality was not different among the groups (p=0.70, p=0.47, and p=0.38, respectively). Mild adverse events were not different among the groups. Conclusion. PR-PFD did not improve the clinical course of sAKI and seemed to be safe in terms of adverse events. This trial is registered with NCT02530359. |
| format | Article |
| id | doaj-art-b4a04280421240d6ac84bcedb139a0b1 |
| institution | Kabale University |
| issn | 2090-214X 2090-2158 |
| language | English |
| publishDate | 2021-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | International Journal of Nephrology |
| spelling | doaj-art-b4a04280421240d6ac84bcedb139a0b12025-02-03T05:52:58ZengWileyInternational Journal of Nephrology2090-214X2090-21582021-01-01202110.1155/2021/88332788833278Effect of Prolonged-Release Pirfenidone on Renal Function in Septic Acute Kidney Injury Patients: A Double-Blind Placebo-Controlled Clinical TrialJonathan S. Chávez-Iñiguez0Jorge L. Poo1Miguel Ibarra-Estrada2Leonel García-Benavides3Guillermo Navarro-Blackaller4Cynthia Cervantes-Sánchez5Eduardo Nungaray-Pacheco6Ramón Medina-González7Juan Armendariz-Borunda8Guillermo García-García9Servicio de Nefrología, Hospital Civil de Guadalajara Fray Antonio Alcalde, Guadalajara, Jalisco, MexicoUnidad de Investigación, ITESM-CCM, Mexico City, MexicoServicio de Unidad de Terapia Intensiva, Hospital Civil de Guadalajara Fray Antonio Alcalde, Guadalajara, Jalisco, MexicoUniversidad de Guadalajara, Centro Universitario de Ciencias de La Salud CUCS, Guadalajara, Jalisco, MexicoServicio de Nefrología, Hospital Civil de Guadalajara Fray Antonio Alcalde, Guadalajara, Jalisco, MexicoServicio de Nefrología, Hospital Civil de Guadalajara Fray Antonio Alcalde, Guadalajara, Jalisco, MexicoServicio de Nefrología, Hospital Civil de Guadalajara Fray Antonio Alcalde, Guadalajara, Jalisco, MexicoServicio de Nefrología, Hospital Civil de Guadalajara Fray Antonio Alcalde, Guadalajara, Jalisco, MexicoUniversidad de Guadalajara, Centro Universitario de Ciencias de La Salud CUCS, Guadalajara, Jalisco, MexicoServicio de Nefrología, Hospital Civil de Guadalajara Fray Antonio Alcalde, Guadalajara, Jalisco, MexicoBackground. There is no treatment for septic acute kidney injury (sAKI). The anti-inflammatory activity of prolonged-release pirfenidone (PR-PFD) could be beneficial in this clinical setting. Methods. This study was a double-blind randomized clinical trial in sAKI patients with nephrology consultation at the Civil Hospital of Guadalajara, in addition to the usual treatment of AKI associated with sepsis; patients were randomized to receive either PR-PFD at 1,200 mg/day (group A) or 600 mg/day (group B) or a matched placebo for 7 consecutive days. The primary objective was the decrease in serum creatinine (sCr) and increase in urinary volume (UV); the secondary objectives were changes in serum electrolytes, acid-base status, and mortality. Results. Between August 2016 and August 2017, 88 patients were randomized. The mean age was 54 (17 ± SD) years, and 47% were male. The main site of infection was the lung (39.8%), septic shock was present in 39.1% of the cases, and the mean SOFA score was 8.8 points. 28 patients received PFD 1,200 mg, 30 patients received PFD 600 mg, and 30 patients received placebo. During the study, sCr did not differ among the groups. The reversion rate of sCr, UV, and mortality was not different among the groups (p=0.70, p=0.47, and p=0.38, respectively). Mild adverse events were not different among the groups. Conclusion. PR-PFD did not improve the clinical course of sAKI and seemed to be safe in terms of adverse events. This trial is registered with NCT02530359.http://dx.doi.org/10.1155/2021/8833278 |
| spellingShingle | Jonathan S. Chávez-Iñiguez Jorge L. Poo Miguel Ibarra-Estrada Leonel García-Benavides Guillermo Navarro-Blackaller Cynthia Cervantes-Sánchez Eduardo Nungaray-Pacheco Ramón Medina-González Juan Armendariz-Borunda Guillermo García-García Effect of Prolonged-Release Pirfenidone on Renal Function in Septic Acute Kidney Injury Patients: A Double-Blind Placebo-Controlled Clinical Trial International Journal of Nephrology |
| title | Effect of Prolonged-Release Pirfenidone on Renal Function in Septic Acute Kidney Injury Patients: A Double-Blind Placebo-Controlled Clinical Trial |
| title_full | Effect of Prolonged-Release Pirfenidone on Renal Function in Septic Acute Kidney Injury Patients: A Double-Blind Placebo-Controlled Clinical Trial |
| title_fullStr | Effect of Prolonged-Release Pirfenidone on Renal Function in Septic Acute Kidney Injury Patients: A Double-Blind Placebo-Controlled Clinical Trial |
| title_full_unstemmed | Effect of Prolonged-Release Pirfenidone on Renal Function in Septic Acute Kidney Injury Patients: A Double-Blind Placebo-Controlled Clinical Trial |
| title_short | Effect of Prolonged-Release Pirfenidone on Renal Function in Septic Acute Kidney Injury Patients: A Double-Blind Placebo-Controlled Clinical Trial |
| title_sort | effect of prolonged release pirfenidone on renal function in septic acute kidney injury patients a double blind placebo controlled clinical trial |
| url | http://dx.doi.org/10.1155/2021/8833278 |
| work_keys_str_mv | AT jonathanschaveziniguez effectofprolongedreleasepirfenidoneonrenalfunctioninsepticacutekidneyinjurypatientsadoubleblindplacebocontrolledclinicaltrial AT jorgelpoo effectofprolongedreleasepirfenidoneonrenalfunctioninsepticacutekidneyinjurypatientsadoubleblindplacebocontrolledclinicaltrial AT miguelibarraestrada effectofprolongedreleasepirfenidoneonrenalfunctioninsepticacutekidneyinjurypatientsadoubleblindplacebocontrolledclinicaltrial AT leonelgarciabenavides effectofprolongedreleasepirfenidoneonrenalfunctioninsepticacutekidneyinjurypatientsadoubleblindplacebocontrolledclinicaltrial AT guillermonavarroblackaller effectofprolongedreleasepirfenidoneonrenalfunctioninsepticacutekidneyinjurypatientsadoubleblindplacebocontrolledclinicaltrial AT cynthiacervantessanchez effectofprolongedreleasepirfenidoneonrenalfunctioninsepticacutekidneyinjurypatientsadoubleblindplacebocontrolledclinicaltrial AT eduardonungaraypacheco effectofprolongedreleasepirfenidoneonrenalfunctioninsepticacutekidneyinjurypatientsadoubleblindplacebocontrolledclinicaltrial AT ramonmedinagonzalez effectofprolongedreleasepirfenidoneonrenalfunctioninsepticacutekidneyinjurypatientsadoubleblindplacebocontrolledclinicaltrial AT juanarmendarizborunda effectofprolongedreleasepirfenidoneonrenalfunctioninsepticacutekidneyinjurypatientsadoubleblindplacebocontrolledclinicaltrial AT guillermogarciagarcia effectofprolongedreleasepirfenidoneonrenalfunctioninsepticacutekidneyinjurypatientsadoubleblindplacebocontrolledclinicaltrial |